Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG: PDS Implant with Ranibizumab 100 mg/mL

Sponsor

Hoffmann-La Roche